A comprehensive view of Eli Lilly & Co.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Eli Lilly partners with digital therapeutics firm Sidekick Health to launch integrated digital therapeutics solution in Germany to provide tailored treatment plan for breast cancer patients; other international markets for solution under consideration
Published: June 30, 2022 by SeeNews Pharmaceuticals
Eli Lilly selling 150,000 doses of monoclonal antibody bebtelovimab co-developed with AbCellera to US government for US$275M, with delivery beginning immediately; bebtelovimab combats COVID-19, offers neutralization activity against all know variants
Published: June 30, 2022 by Business Wire
Eli Lilly supplying Aveo Oncology with Erbitux cetuximab for North American clinical trial evaluating Aveo’s ficlatuzumab with cetuximab to treat metastatic head, neck squamous cell carcinoma; Merck KGaA providing cetuximab outside of US, Canada
Published: June 23, 2022 by GlobeNewswire
FDA approves Eli Lilly’s Olumiant oral treatment for alopecia areata, an autoimmune disorder that causes sudden hair loss; once-daily pill is first treatment of its kind and is available by prescription only
Published: June 14, 2022 by STAT News
FDA approves Eli Lilly’s NDA oral Olumiant tablet containing baricitinib 1 mg, 2 mg in 2 formulations; drug is available by prescription only and has no therapeutic equivalents
Published: June 01, 2022 by US Food and Drug Administration News (CBNB Abstracts)

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count